DrugsControl Media Services
DrugsControl.org

News Detail

FTC targeting more than 300 Junk Listings for Diabetes, Weight Loss, Asthma and COPD Drugs (01-05-2024)

WASHINGTON, 1 MAY 2024:  the Federal Trade Commission expanded its campaign against pharmaceutical manufacturers’ improper or inaccurate listing of patents in the Food and Drug Administration’s (FDA) Orange Book, disputing junk patent listings for diabetes, ......
View Details

Source : Federal Trade Commission
Ozempic pharmaceutical industry practices Federal Trade Commission warning letters Novo Nordisk GlaxoSmithKline AstraZeneca

Related News